Company intelligence / Profile preview
Evrys Bio
King of Prussia, Pennsylvania, United Statesevrysbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Evrys Bio has demonstrated excellent preclinical activity of proprietary sirtuin-targeting small molecules against a range of viruses including coronaviruses and influenza. The company has received significant non-dilutive funding to advance these candidates toward the clinic, with a focus on broad-spectrum antivirals that reduce the risk of drug resistance.[4][5] No published human clinical results yet.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (sirtuin modulators)[1][2][3]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
U.S. Department of Defense ($34M contract for development of broad-spectrum antivirals)[4]
Beyond the preview
Go deeper on Evrys Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evrys Bio.